Lupus nephritis

This phase 2 trial is testing whether a single infusion of a patient's own genetically modified immune cells, called C-CAR168, can safely and effectively treat lupus nephritis that has not responded to standard therapies. The cells are designed to target and eliminate specific im…

This early-phase trial tests whether a single infusion of CD19 CAR-T cells, called TranspoCART19, is safe and can push severe lupus nephritis into remission. Lupus nephritis is a serious kidney complication of lupus that often resists standard treatments. Ten adults with refracto…

This early-stage trial is testing an experimental drug called SNC116 in people with refractory systemic lupus erythematosus (SLE), a form of lupus that hasn't improved with standard treatments. The study aims to see if a single intravenous infusion of SNC116 is safe and tolerable…

This phase 3 trial is testing whether adding the drug obinutuzumab to the standard treatment (mycophenolate mofetil and corticosteroids) can improve outcomes for people with active lupus nephritis, a serious kidney complication of lupus. The study will enroll 70 adults aged 18-65…

This study evaluates a new care model for people with lupus nephritis, a kidney complication of lupus. The approach uses telemedicine visits and clinical pharmacist practitioners to provide medication support, adherence help, and remote monitoring, with oversight from specialists…

This phase 1 trial tests an experimental cell therapy called LMY-922 (BAFF CAR-T cells) in people aged 16 to 75 with refractory autoimmune diseases, including rheumatoid arthritis, lupus, dermatomyositis, and systemic sclerosis. The therapy uses donor immune cells engineered to t…

This phase II trial tests whether obinutuzumab, a B-cell targeting antibody, can alone achieve complete kidney response in people with pure class V lupus nephritis—a form of lupus kidney disease with no approved treatments. Participants receive up to four infusions over seven mon…

This study tests whether combining rituximab with a low dose of mycophenolate mofetil can safely and effectively treat lupus nephritis in children. Lupus nephritis is a serious kidney complication of lupus. The trial enrolls children aged 3 to 18 with active kidney inflammation. …

This early-phase trial tests a single infusion of universal CAR-T cells (RD06-05) in 30 children and adolescents with severe autoimmune diseases, including lupus, scleroderma, and kidney inflammation. The cells are designed to target and calm overactive immune cells. The main goa…

This trial tests a one-time treatment called CAR-T cell therapy for people with systemic lupus erythematosus (lupus) that hasn't improved with standard medications. The therapy uses a patient's own immune cells, which are modified in a lab to find and destroy the B cells that dri…

This early study tests a new drug called MTM-H-001 in 75 adults with B-cell-related autoimmune diseases, including lupus, multiple sclerosis, and rheumatoid arthritis. The main goal is to check safety and find the right dose. Participants receive the drug by injection, and resear…

This early-phase study tests a new treatment using specially engineered immune cells (CD19 CAR-γδ T cells) for people with severe autoimmune kidney diseases like lupus nephritis, IgA nephropathy, and membranous nephropathy that haven't responded to standard therapies. About 15 pa…

This study tests whether regularly measuring the amount of mycophenolate mofetil in the blood helps more people with lupus kidney disease achieve kidney remission. One hundred adults with active lupus nephritis will be split into two groups: one gets standard dosing, the other ge…

This early study tests a new treatment called ES-NK cells for people with severe lupus nephritis that hasn't responded to standard care. The therapy uses specially grown immune cells to try to control the disease. About 5 to 9 participants will receive different doses to check sa…

This study tests a new drug, SIM0278, in 60 adults with active lupus nephritis, a kidney disease caused by lupus. Participants will receive either SIM0278 or a placebo, and researchers will check if the drug helps improve kidney function over 52 weeks. The goal is to see if SIM02…

This early study tests a new drug called STR-P004 in 9 adults with immune-mediated kidney diseases. The goal is to see if the drug is safe and how the body processes it. Participants receive up to 8 infusions over 28 days, with possible dose increases. This is not a cure; it aims…

This early-phase trial is testing a new treatment called CRC01 for people with severe lupus nephritis, a serious kidney complication of lupus. The therapy uses a patient's own immune cells, which are modified in a lab to target and destroy certain immune cells that drive the dise…

This observational study tests whether levels of MPO-DNA complexes in the blood can serve as a reliable biomarker for disease activity in systemic lupus erythematosus (SLE). Researchers will compare MPO-DNA levels in 90 participants with active versus inactive lupus, and check ho…

This study asks whether levels of uromodulin, a protein in the blood, can indicate the severity of kidney damage in people with lupus nephritis. Researchers will compare uromodulin levels with kidney biopsy results from 90 participants, including those with different classes of l…

This study investigates whether levels of a protein called RNASE1 in the blood can serve as a biomarker for lupus nephritis, a serious kidney complication of systemic lupus erythematosus (SLE). Researchers will compare RNASE1 levels in 128 adults with SLE, some with lupus nephrit…

Lupus nephritis is a serious kidney complication of lupus that can lead to kidney failure. This study investigates whether levels of neutrophil extracellular traps (NETs)—web-like structures released by immune cells—in the blood can predict how well patients respond to therapy. R…

This study looks at whether measuring anti-alpha-actinin antibodies in the blood can help identify active lupus nephritis (kidney inflammation) in people with lupus. Researchers will compare antibody levels with findings from standard kidney biopsies in 96 adults. If the blood te…

This study looks at whether two simple blood test ratios—neutrophil-to-lymphocyte ratio (NLR) and C-reactive protein to serum albumin ratio (CAR)—can predict which hospitalized adults with lupus nephritis will need intensive care or die during their stay. Researchers will compare…

This study follows 300 adults in China who have had a kidney transplant due to glomerulonephritis (GN), a type of kidney disease. The goal is to see how often GN comes back after the transplant and what factors might influence that. Participants will be monitored for three years …

This study looks at whether two blood-based inflammation markers, called SII and SIRI, can help track disease activity and predict kidney flares in people with lupus nephritis, a type of kidney inflammation caused by lupus. Researchers will follow 100 adults with confirmed lupus …

This study investigates whether the triglyceride-glucose (TyG) index, a simple blood-based measure of insulin resistance, can predict early signs of atherosclerosis in people with lupus nephritis. Researchers will measure carotid artery thickness and plaque in 156 adults with lup…

This trial tests an AI-powered teaching platform called iLN, which uses a large language model to help medical students learn about lupus nephritis. Fifty fourth-year medical students are randomly assigned to either use iLN or attend a traditional PowerPoint lecture. The study me…

This study will check if people with lupus nephritis have low zinc levels and how that relates to kidney function. Researchers will measure zinc, urea, creatinine, and other markers in 75 participants. The goal is to better understand the connection, not to test a treatment.

This study will measure levels of a protein called IL-33 in the blood of 150 people: lupus patients with kidney inflammation, lupus patients without kidney issues, and healthy volunteers. Researchers want to see if higher IL-33 levels are linked to more severe disease, especially…